The EORTC 10041/BIG 03-04 MINDACT trial is feasible: Results of the pilot phase

The logistically complex MINDACT trial is feasible in a multinational setting. The proportion of discordant patients, the potential reduction in CT by using the genomic signature and compliance to treatment assignment are in accordance with the trial hypotheses.